Treatment of chronic mucocutaneous candidosis with ketoconazole: a study of 12 cases.
Twelve patients with chronic mucocutaneous candidosis were treated orally with ketoconazole (doses, 200-400 mg daily) for a mean period of six months. Seven of the patients had one of the following abnormalities: congenital endocrinopathy syndrome, an autosomal recessive or autosomal dominant defect in which candidosis is not associated with endocrinopathy, or the malabsorption syndrome. All patients had fungal infections of the mouth, and 11 had onychomycosis. Two patients were also infected with dermatophytes. At the end of treatment, 10 patients were cured of oral infection, and 11 with nail infections showed significant improvement. Marked improvement of hand and foot infections was also recorded. Patients infected with dermatophyte fungi had the poorest responses to therapy. The mean (+/- SD) MIC for isolates of Candida albicans from eight patients was 0.95 (+/- 0.78) microgram/ml. Clinical and biochemical monitoring showed no toxicity, and no resistant fungi emerged during treatment. Results of this initial study of ketoconazole for treatment of severe and recalcitrant superficial infections indicate the need for further assessment of this drug, which appears to offer a simple, nontoxic, and effective treatment of fungal infections.
D000293:Adolescent; D000328:Adult; D002176:Candida albicans / Q000302:isolation & purification; D002177:Candidiasis / Q000188:drug therapy*; D002178:Candidiasis, Chronic Mucocutaneous / Q000188:drug therapy*; D002179:Candidiasis, Cutaneous / Q000188:drug therapy; D002180:Candidiasis, Oral / Q000188:drug therapy; D002648:Child; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000097:blood / Q000627:therapeutic use*; D007654:Ketoconazole; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D010879:Piperazines / Q000097:blood / Q000627:therapeutic use*
D007093:Imidazoles; D010879:Piperazines; D007654:Ketoconazole